Triple-Negative Breast Cancer Medical Services in China

Triple-negative breast cancer (TNBC) is an aggressive subtype of invasive ductal carcinoma characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression—hence “triple-negative.” Accounting for 10–15% of all breast cancers, TNBC disproportionately affects younger women and those with BRCA1 mutations, and it carries a higher risk of early recurrence, distant metastasis, and poorer overall survival compared to hormone receptor–positive or HER2-positive subtypes. Treatment relies primarily on multimodal strategies: neoadjuvant or adjuvant chemotherapy (e.g., anthracycline/taxane-based regimens), surgical resection (lumpectomy or mastectomy), and radiation therapy. Recent advances include immune checkpoint inhibitors (e.g., pembrolizumab) combined with chemotherapy for PD-L1–positive locally advanced or metastatic disease, as well as PARP inhibitors for BRCA-mutated cases.

China offers compelling advantages for TNBC management: leading oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—maintain internationally accredited tumor boards, extensive clinical trial portfolios (including NMPA- and FDA-aligned studies), and access to cutting-edge technologies like digital pathology, next-generation sequencing, and AI-enhanced radiotherapy planning. Five-year survival rates for early-stage TNBC in top-tier Chinese hospitals align closely with global benchmarks, supported by robust real-world outcome data from large cohort studies. Crucially, treatment costs—including genomic profiling, immunotherapy, and surgery—are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or multidisciplinary care standards.

As a dedicated medical tourism agency, we facilitate seamless access for international patients: vetting JCI-accredited hospitals, coordinating appointments with TNBC-specialized oncologists, providing transparent, all-inclusive pricing (covering diagnostics, treatment, accommodation, and interpreter services), and offering end-to-end support—from visa assistance to post-treatment follow-up coordination.

Treatment Options & Itemized Cost Breakdown: Triple-Negative Breast Cancer (TNBC)

Non-Surgical/Medical Therapies

*Eligibility*: Confirmed TNBC (ER/PR/HER2-negative) by IHC/FISH; stage I–IV; adequate organ function (LVEF ≥50%, ANC ≥1.5×10⁹/L, creatinine clearance ≥60 mL/min).

• •Neoadjuvant Chemotherapy (Standard for Stage II–III):

- *Drug cost*: $1,280–$1,920 (paclitaxel: $320–$480/dose × 12; carboplatin: $720–$1,080/dose × 4) - *Supportive care*: G-CSF ($120–$180/dose × 2–4), antiemetics ($25–$45/dose × 12) - *Monitoring*: CBC/chemistry weekly ($18–$28/test), cardiac echo pre-cycle 1 ($110), CT chest/abdomen/pelvis pre/post ($220–$330)

• •Adjuvant Immunotherapy (PD-L1+ tumors, stage II–III):

- *Drug cost*: $2,880–$3,600 ($320–$400/dose) - *Biomarker testing*: PD-L1 IHC (SP142 assay) — $180

• •Metastatic Setting (1st-line):

- *Sacituzumab govitecan*: $4,800–$6,000 (10 mg/kg IV q2w × 4 cycles; $1,200–$1,500/dose)

Surgical/Procedural Interventions

*Eligibility*: Clinically resectable disease (cT1–4, N0–2, M0); ECOG 0–2; no contraindications to anesthesia.

• •Breast-Conserving Surgery (BCS) + Sentinel Lymph Node Biopsy (SLNB):

- *Pre-op workup*: Mammogram + ultrasound ($180), MRI ($360), core biopsy ($120), SLN mapping (Tc-99m + blue dye, $240)

• •Modified Radical Mastectomy (MRM):

- *Pre-op workup*: Same as BCS + chest wall CT ($220) if high-risk features

• •Axillary Lymph Node Dissection (ALND):

Special/Complex Scenarios

• •BRCA1/2 Mutation Carriers:

- *PARP inhibitor (olaparib)*: $2,400–$3,000/month (maintenance after platinum chemo)

• •Brain Metastases:

- *Stereotactic radiosurgery (SRS)*: $2,880–$4,320 (single fraction)

Quick Selection Guide

• •Early-stage (I–II), <65 y, no comorbidities: BCS + SLNB ($2,160–$2,880) → neoadjuvant chemo ($1,280–$1,920) → adjuvant pembrolizumab if PD-L1+ ($2,880–$3,600). *Total estimated*: $6,320–$8,400.
• •Locally advanced (III), BRCA+: Neoadjuvant chemo + immunotherapy → MRM + ALND ($2,880–$3,600 + $960–$1,200) → olaparib maintenance ($2,400–$3,000/month). *Initial procedural cost*: $3,840–$4,800.
• •Metastatic, budget-constrained (<$3,000): Gemcitabine/carboplatin ($1,440–$2,160) + supportive care. Avoid sacituzumab unless progression on chemo.
• •Elderly (>75 y) or frail (ECOG ≥3): Palliative single-agent capecitabine ($480–$720/course) + symptom management. Pre-op labs only ($180–$240).